In a statement sent to Fierce Pharma Marketing, Cristian Azcarate, argenx’s VP of patient strategy, said the company’s work ...

Johnson & Johnson's (J&J) human neonatal Fc receptor (FcRn)-blocking monoclonal antibody Imaavy (nipocalimab-aahu) has ...

The Food and Drug Administration (FDA) has approved Imaavy™ (nipocalimab-aahu) for the treatment of generalized myasthenia gravis (gMG) in adult and pediatric patients aged 12 years and older who are ...

Alina, was then working as a teacher at a secondary school in Kajang, Selangor. Initially, she thought her condition was due ...

For details, see the “Before receiving Ultomiris” section. With myasthenia gravis, dysfunctional muscle ... begins with a loading dose. Two weeks after the loading dose, you’ll continue ...

While Johnson & Johnson isn't the first to secure FDA approval for an FcRn-blocking antibody in myasthenia gravis, the New ...

May 2, 2025 -- The FDA has approved a new treatment for generalized myasthenia gravis (gMG ... or redness of skin during or a few days after Imaavy infusion. Before or during treatment, patients ...

Changes in intravenous or subcutaneous immunoglobulin usage before and after efgartigimod initiation in patients with myasthenia gravis. Poster presented at: AMCP 2025; March 31-April 3 ...

Johnson & Johnson ’s anti-FcRn antibody nipocalimab has been approved by the FDA to treat generalized myasthenia gravis. The ...

Highlights in myasthenia gravis (MG) from the American Academy of Neurology 2025 Annual Meeting include new therapy trials and practice reviews, as discussed by Dr Nicholas Silvestri of the ...

Adult and pediatric generalized myasthenia gravis patients have a new, longer acting option for treatment called Imaavy.

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis ... 2 weeks via IV infusion after dilution.